BioMarin Pharmaceutical Inc. (BMRN)
$
57.54
-0.46 (-0.80%)
Key metrics
Financial statements
Free cash flow per share
3.6117
Market cap
11 Billion
Price to sales ratio
3.6171
Debt to equity
0.0989
Current ratio
5.5613
Income quality
1.1667
Average inventory
1.3 Billion
ROE
0.1148
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
BioMarin Pharmaceutical Inc. specializes in the development and commercialization of therapies aimed at addressing serious and life-threatening rare diseases and medical conditions. The company’s portfolio includes Vimizim, an enzyme replacement therapy for mucopolysaccharidosis (MPS) IV type A; Naglazyme, a recombinant enzyme for treating MPS VI; and Kuvan, a synthetic oral treatment for phenylketonuria (PKU). Additionally, the product lineup features Palynziq, which is a PEGylated recombinant enzyme administered via subcutaneous injection to lower blood Phe levels; Brineura, designed for ceroid lipofuscinosis type 2; and Voxzogo, a daily injection aimed at treating achondroplasia. Another key product, Aldurazyme, is a purified protein mimicking the natural human enzyme alpha-L-iduronidase. BioMarin is also progressing with valoctocogene roxaparvovec in Phase III trials for severe hemophilia A, BMN 307 in Phase 1/2 trials for PKU, and BMN 255 in Phase 1/2 trials targeting primary hyperoxaluria. The total costs and expenses for the company are $2,369,701,000.00 reflecting its overall spending. The gross profit ratio is 0.80 indicating the efficiency of the company's production and sales operations. Furthermore, the company recorded a net income of $426,859,000.00 highlighting its profitability. Depreciation and amortization expenses of $96,426,000.00 are reported, reflecting the wear and tear of its assets, against a substantial revenue of $2,853,915,000.00 showcasing its strong market presence. As a publicly traded entity, BioMarin's stock is reasonably priced at $58.23 appealing to a broad range of investors. The stock maintains a high average trading volume of 2,313,006.00 indicating robust liquidity. With a mid-range market capitalization of $11,048,543,100.00 the company is recognized as a steady performer. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Additionally, BioMarin operates within the Healthcare sector, driving innovation and growth, which positions it favorably among its peers. This dynamic combination of product offerings and market strategies underscores BioMarin's commitment to enhancing the lives of patients facing rare diseases.
Is BioMarin Pharmaceutical Inc. (BMRN) a good investment?
Investing in BioMarin Pharmaceutical Inc. (BMRN) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as A, with a Bearish outlook. Always conduct your own research before investing.
What is BioMarin Pharmaceutical Inc. (BMRN)'s stock forecast?
Analysts predict BioMarin Pharmaceutical Inc. stock to fluctuate between $52.93 (low) and $94.85 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is BioMarin Pharmaceutical Inc.'s market capitalization?
As of 2025-08-18, BioMarin Pharmaceutical Inc.'s market cap is $11,048,543,100, based on 192,015,000 outstanding shares.
How does BioMarin Pharmaceutical Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., BioMarin Pharmaceutical Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy BioMarin Pharmaceutical Inc. (BMRN) stock?
To buy BioMarin Pharmaceutical Inc. (BMRN) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for BMRN. Place an order (Market, Limit, etc.).
What is the best time to invest in BioMarin Pharmaceutical Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did BioMarin Pharmaceutical Inc. perform in the last earnings report?
Revenue: $2,853,915,000 | EPS: $2.13 | Growth: 139.33%.
Where can I find BioMarin Pharmaceutical Inc.'s investor relations reports?
Visit https://www.biomarin.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for BioMarin Pharmaceutical Inc.?
You can explore historical data from here
What is the all-time high and low for BioMarin Pharmaceutical Inc. stock?
All-time high: $117.77 (2023-01-27) | All-time low: $52.93 (2025-04-09).
What are the key trends affecting BioMarin Pharmaceutical Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
zacks.com
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
zacks.com
BMRN's Q2 earnings surge 50% on strong Voxzogo and enzyme therapy sales, prompting a raised 2025 revenue and EPS outlook.
seekingalpha.com
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN ) Q2 2025 Earnings Conference Call August 4, 2025 4:30 PM ET Company Participants Alexander Hardy - President, CEO & Director Brian R. Mueller - Executive VP of Finance & CFO Cristin Hubbard - Executive VP & Chief Commercial Officer Gregory Friberg - Executive VP and Chief Research & Development Officer Traci McCarty - Group Vice President Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Alexandria Janet Hammond - Wolfe Research, LLC Allison Marie Bratzel - Piper Sandler & Co., Research Division Cory William Kasimov - Evercore ISI Institutional Equities, Research Division Ellen Horste - TD Cowen, Research Division Huidong Wang - Barclays Bank PLC, Research Division Jasmine Alexandra Fels - UBS Investment Bank, Research Division Jason Matthew Gerberry - BofA Securities, Research Division Konstantinos Biliouris - BMO Capital Markets Equity Research Olivia Simone Brayer - Cantor Fitzgerald & Co., Research Division Paul Andrew Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division Sean M.
zacks.com
Although the revenue and EPS for BioMarin (BMRN) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
zacks.com
BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $1.44 per share, beating the Zacks Consensus Estimate of $1.03 per share. This compares to earnings of $0.96 per share a year ago.
zacks.com
BioMarin (BMRN) possesses solid growth attributes, which could help it handily outperform the market.
zacks.com
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
zacks.com
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
zacks.com
BioMarin (BMRN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
See all news
